|Bid||69.76 x 1000|
|Ask||69.86 x 1100|
|Day's Range||66.25 - 71.17|
|52 Week Range||33.33 - 130.33|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||13.12|
|Earnings Date||Oct. 28, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||100.10|
Ingevity (NGVT) to boost caprolactone monomer production at its Warrington unit to more effectively cater to the rising demand in its engineered polymers portfolio.
Daqo (DQ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The consensus price target hints at a 25.5% upside potential for Daqo (DQ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.